Drawing from research from across the breadth of Norstella, this white paper lays out the argument for the increasing strategic influence of patient access. The pricing and reimbursement landscape in the US remains volatile as the various stakeholders react to new policies and the increasing complexity of new drug launches. This is creating the conditions by which access strategy must inform the upstream R&D approach, rather than purely being led by data generated through drug development. This fundamental shift raises the importance of market access and places it at the heart of decision-making throughout the pipeline-to-patient journey.
Investment in access capabilities, whether in terms of corporate prioritization, data analytics solutions, and consulting services must grow to stay ahead of this trend. In turn, this will help biopharma companies to choose and accelerate the right treatments to develop, embedding not just technical and regulatory risk into their calculus, but also the access environment. This will see the shift in therapeutic priorities continue, as pipelines rebalance toward a more comprehensive assessment of patient need and eventual success in the market.
Please read the full report to learn more or contact us to explore any of the themes discussed in further detail.
